Dimosthenis Mantopoulos, MD
Ophthalmology · New Brunswick, NJNPI 1679816326
Payments from drug & device makers
Across 49 payments — averaging $95.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$2K
- Alcon$1K
- Regeneron Healthcare Solutions, Inc.$523
- Astellas Pharma US Inc$260
- ANI Pharmaceuticals, Inc.$70
- AbbVie$53
- plus $164 from 5 others
What the payments were for
- Speaking & faculty fees$2,14046%
- Travel & lodging$1,10824%
- Food & beverage$1,42730%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 6 | $2,207 |
| Alcon | 3 | $1,411 |
| Regeneron Healthcare Solutions, Inc. | 18 | $523 |
| Astellas Pharma US Inc | 9 | $260 |
| ANI Pharmaceuticals, Inc. | 4 | $70 |
| AbbVie | 3 | $53 |
| Bausch & Lomb Americas Inc. | 2 | $48 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $43 |
| Sandoz | 1 | $30 |
| Genentech USA, Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,688 in reported general payments places this provider in the 80th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 78 | $4,431 |
| Bromfenac Sodium | 13 | $1,231 |
| Ketorolac Tromethamine | 29 | $1,049 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $428 |
| Difluprednate | 12 | $407 |
| Latanoprost | 30 | $289 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 15 | $107 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in New Brunswick
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.